.svg)
What's the Problem?
Today there is a limited access to molecular diagnostics in developing countries. This limitation occurs because of high equipment investment and high costs of consumables. Also, a lack of local technical assistance for recognized brands doing molecular diagnostics limits the possibilities. Leader companies need a high number of samples per platform use and have specific facilities requirements which make more difficult its implementation.
How are they Solving it?
ZEV Biotech has developed a complete Genomic Platform for molecular diagnosis adapted to developing countries market needs: -Modular equipment and low investment, allowing easy and cost-effective implementation -Low consumables costs -Scalable: Low number of samples per platform use -Versatile. Different pathologies can be diagnosed in the same platform use -Internal Quality Controls -Adaptable to every laboratory workflow -Internationaly validated.
b.jpg)
Next Startup
AlgaeBio+
.svg)